Hoth Therapeutics receives approval for HT-KIT cancer program patent in China

Hoth Therapeutics (HOTH) announced that the China National Intellectual Property Administration has approved issuance of a key patent covering the Company’s HT-KIT cancer program, a novel therapeutic approach designed to induce apoptosis in disease-driving cells by targeting KIT signaling pathways. The patent, which originated from a PCT international application, provides important intellectual property protection in China, one of the world’s largest and fastest-growing oncology markets, and further strengthens Hoth’s global IP estate surrounding HT-KIT. HT-KIT is designed to disrupt aberrant KIT-driven signaling, a pathway implicated in multiple cancers, by leveraging splice-switching and molecular targeting strategies aimed at triggering programmed cell death. This mechanism is intended to selectively impact disease-relevant cells while avoiding broader systemic toxicity associated with traditional cytotoxic therapies.